Pramlintide Review: Amylin Analogue Improves Blood Sugar and Weight With Good Heart Safety | Research

The takeaway

This review evaluates pramlintide's efficacy as insulin adjunct therapy, showing HbA1c and weight reduction with minimal hypoglycemia, alongside cardiovascular safety data and comparison with GLP-1 receptor agonists.

Fills the insulin gap
Pramlintide addresses what insulin alone cannot: postprandial glucagon excess, rapid gastric emptying, and appetite — reducing both HbA1c and weight when added to insulin

What the researchers found

Pramlintide with insulin reduces HbA1c and weight with minimal/no hypoglycemia in T1DM and T2DM. Mechanisms: delayed gastric emptying, glucagon suppression, appetite reduction. Cardiovascular safety appears favorable. Shares mechanisms with GLP-1 RAs.

Why it matters

Pramlintide fills a treatment gap: patients on insulin who still have poor control and are gaining weight. Its unique mechanism (amylin replacement) addresses diabetes pathophysiology that insulin alone cannot fix.

The numbers in context

Pramlintide improves HbA1c, promotes weight loss, delays gastric emptying, suppresses postprandial glucagon; favorable CV safety profile

How the study worked

Narrative review of clinical trial evidence on pramlintide efficacy (HbA1c, weight, cognition), safety (hypoglycemia, cardiovascular), and comparison with GLP-1 receptor agonists when used as insulin adjunct therapy.

Who was studied

Adults with type 1 and type 2 diabetes on insulin therapy

What this study cannot tell us

Three daily injections limit adherence. Review does not include head-to-head pramlintide vs GLP-1RA trials. Weight loss is modest compared to newer GLP-1 drugs. Limited cognition data available. Pramlintide is underused in clinical practice.

How to read the evidence

Moderate evidence (review of clinical trial data). Based on approved drug's clinical evidence but lacking large head-to-head comparison trials.

When this study was published

Published 2021. Cagrilintide (long-acting amylin analogue) is being developed to address pramlintide's dosing limitations.

The bigger picture

Pramlintide validates amylin as a therapeutic target in diabetes. Its limitations (three daily injections) are being addressed by next-generation long-acting amylin analogues like cagrilintide, which could make amylin-based therapy more practical.

Questions still open

Would long-acting amylin analogues (like cagrilintide) produce greater benefits than pramlintide?
Is pramlintide + GLP-1RA combination more effective than either alone?
Should pramlintide be considered more frequently given its weight and glycemic benefits?

Common questions

What is pramlintide and who should consider it?

Pramlintide (Symlin) is a synthetic version of amylin, a hormone normally co-secreted with insulin. It's for diabetes patients already on insulin who struggle with blood sugar control and/or weight gain. It reduces blood sugar spikes after meals and decreases appetite.

How does pramlintide compare to GLP-1 drugs like Ozempic?

Both reduce blood sugar and weight. GLP-1 drugs are typically more convenient (weekly injection) with greater weight loss. Pramlintide requires three daily injections but targets a different pathway (amylin). Some patients benefit from combining both approaches.

Read the original research

A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues.

Current drug safety, 16(2), 129-141

View on PubMed ↗Publisher’s paper ↗

Citation

Koshy, Rithika Mary; Fernandez, Cornelius James; Jacob, Koshy. (2021). A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues.. Current drug safety, 16(2), 129-141. https://doi.org/10.2174/1574886315999201105153852